Managers / Q1 2026
CIM INVESTMENT MANAGEMENT INC
CIK 0001179791 · 436 SEVENTH AVENUE, KOPPERS BUILDING SUITE 2600, PITTSBURGH, PA, 15219 · 4127652771
Summary
Cim Investment Management Inc reported $375M in U.S.-listed holdings across 251 positions for Q1 2026.
The portfolio is heavily concentrated: Ishares S P 500 Index alone accounts for 21.7% of reported value.
Compared with Q4 2025, the fund opened 18 new positions and exited 14.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 61.9% · $232M
- ETP · 34.3% · $129M
- REIT · 2.2% · $8M
- Other · 1.2% · $5M
- ADR · 0.3% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2025 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Fabrinet | NEW | +1.0K | 1.0K | +$540,295 | $540,295 |
| IONQIONQ, Inc. | NEW | +16.7K | 16.7K | +$480,510 | $480,510 |
| Lyondell Basell Indu-Cl A | NEW | +4.6K | 4.6K | +$367,515 | $367,515 |
| ELFELF Beauty Inc. | NEW | +6.0K | 6.0K | +$366,084 | $366,084 |
| RMBS*Rambus Inc. | NEW | +4.1K | 4.1K | +$350,314 | $350,314 |
| Noble Corp | NEW | +7.0K | 7.0K | +$345,453 | $345,453 |
| CN2Catalyst Pharmaceuticals Inc | NEW | +12.5K | 12.5K | +$310,416 | $310,416 |
| CYTKCytokinetics Inc. | NEW | +4.7K | 4.7K | +$308,327 | $308,327 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2026
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $375M | 251 | May 19, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $382M | 247 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $369M | 249 | Nov 18, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $525M | 424 | Aug 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $342M | 249 | Feb 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $338M | 254 | Nov 25, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $324M | 255 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $336M | 285 | May 7, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $310M | 287 | Feb 16, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $273M | 278 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $294M | 278 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $270M | 267 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $254M | 248 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $225M | 224 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $334M | 299 | May 19, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2021 | $652M | 598 | Feb 2, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $318M | 299 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $323M | 299 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $318M | 298 | May 20, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $308M | 285 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $263M | 258 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $248M | 252 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $204M | 197 | May 22, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $253M | 235 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $268M | 315 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $273M | 315 | Aug 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $260M | 309 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $230M | 296 | Feb 5, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.